Thomas is a French ECVP board-certified veterinary toxicologic, experimental and comparative pathologist with 30 years of experience. Thomas started his career as a diagnostician and research immuno-pathologist in the United States and received his PhD from Louisiana State University in 2000. He then joined the biopharmaceutical industry in Europe as a research and regulatory safety pathologist in Servier then Eli Lilly & Company. Thomas moved to the CRO arena in 2007 to develop TCR and IHC/ISH assays and has contributed to over hundreds of studies. Thomas is currently embracing and leading the digital revolution in pathology at StageBio and is specialized in in situ molecular techniques and investigative/efficacy studies in animal models out of TPL Path Labs GmbH, a company of StageBio, based in Freiburg, Germany. Thomas helps clients design the best possible clinical and non-clinical efficacy or safety investigative studies and is leading implementation of in situ molecular assays and quantitative pathology projects, along with performing pathology evaluations.
Dr. Mike Betley comes to StageBio from Inotiv where he served as a study pathologist for preclinical safety and drug efficacy studies in laboratory animals. Dr. Betley grew up in the Saint Louis region and earned his DVM from the University of Missouri in 2011. Following graduation, he entered the Neurosciences PhD program at Stanford University where his thesis research focused on the connection between aerobic exercise and adult hippocampal neurogenesis. He graduated with his PhD in 2016 and moved to Fort Collins, CO to complete his pathology residency training at Colorado State University. Dr. Betley is looking forward to utilizing his pathology skills and neuroscience research training to serve the needs of StageBio’s Neuropathology clients. When he’s not working, you can find Dr Betley spending time outdoors cycling, playing golf and fishing.
Dr. Amy Brix joins StageBio after working for EPL, Inc. in North Carolina for over 22 years, the last 11 of which were spent on-site at the National Institute of Environmental Health Sciences, in the Division of the National Toxicology Program. Dr. Brix did her residency at the University of Georgia, where she worked with Duke University to develop a canine model of von Gierke’s disease (glucose-6-phosphatase deficiency). She also did her graduate studies at Georgia, examining the effect of growth factors on the production of glycosaminoglycans and proteoglycans in cell culture. Following her PhD, she did a post-doctoral fellowship in comparative medicine at the University of Alabama at Birmingham, looking at several genetically modified mouse models of human disease. She is excited to be part of the StageBio Team!
Dr. Elcock has more than 30 years of experience as a toxicologic veterinary pathologist, serving as the primary study pathologist for 500-plus GLP preclinical studies in the pharmaceutical and agricultural industries. She has a particular interest in reproductive pathology and has evaluated more than 15 peer-reviewed carcinogenicity studies in a variety of mouse and rat strains.
Dr. Elcock earned her DVM in 1982, as well as her MS and PhD in Veterinary Pathology in 1983 and 1985, respectively, all from Kansas State University. She became a Diplomate of the American College of Veterinary Pathologists in 1987.
Dr. Friedemann completed her residency in anatomic & cardiovascular pathology at Texas A&M University, where she received specialized training in medical device pathology and earned her master's degree (Biomedical Sciences). Dr. Friedemann is a Diplomate of the American College of Veterinary Pathologists (ACVP) and is an active member of ACVP as well as the Society of Toxicologic Pathology (STP). Her primary interests include cardiovascular and orthopedic devices, as well as working with subcutaneous biosensors and resorbable materials.
We are pleased to welcome Jessica Hoane, DVM, MTOX, DACVP, DABT to the StageBio team! Jessica comes to us from Charles River Laboratories in Durham, North Carolina, where she spent nearly a decade cultivating expertise in safety assessment and organizing pathology working groups for the National Toxicology Program. Prior to joining CRL, she spent three years at MPI Research in Mattawan, Michigan. Jessica received her D.V.M. from Michigan State University, where she also completed a residency in veterinary anatomic pathology. She more recently earned a Master of Toxicology (MTOX) degree from North Carolina State University and became a Diplomate of the American Board of Toxicology. Prior to pursuing veterinary pathology, she spent five years as a Graduate Research Assistant at the University of Kentucky studying equine antibody response to surface antigens of Sarcocystis neurona and the Neospora hughesi. Jessica has instructed undergraduate and veterinary students at several institutions in anatomy, physiology, and histology and has served as an Associate Editor of the journal Toxicologic Pathology.
Dr. Crystal Johnson comes to StageBio from Charles River Laboratories, Inc. (CRL) in Durham, North Carolina. Dr. Johnson completed her Doctor of Veterinary Medicine at North Carolina State University, College of Veterinary Medicine in 1995. She joined Charles River Laboratories as a rodent surgeon immediately after veterinary school before joining Pathology Associates International (PAI) where she held a variety of positions including histology/necropsy technician and research associate. Charles River purchased PAI in 2000 and in 2006 Dr. Johnson proposed returning to school to pursue a residency in anatomic pathology. While in her residency, she continued to work limited hours at CRL and received her board certification with the American College of Veterinary Pathologists in 2010.
Dr. Johnson has special expertise in inhalation studies, female reproductive pathology and endocrine disruption, and in several animal models including pancreatic cancer, colitis, xenotransplantation, and orphan diseases.
In her spare time, she likes to put her crafting skills to work on various artistic hobbies including building miniature models and designing and assembling laser cut items.
Dr. Morgan’s professional interests include the use of animal models of disease in drug development. Prior to joining StageBio, she worked at Abbott/AbbVie and provided pathology support across multiple therapeutic indications. She has authored numerous peer-reviewed publications. Dr. Morgan received her DVM from Kansas State University (1980) and her PhD in pathology from Texas A&M University (1988). She is a Diplomate of the American College of Veterinary Pathologists, the American Board of Toxicology, and the American Board of Veterinary Toxicology.
Dr. Jaime Paulin’s interests range from medical device pathology and toxicologic pathology to diagnostic pathology. He joined StageBio after previously evaluating a wide range of medical devices for 12 years at a major medical device company. He has supported more than 400 independent studies, ranging from proof-of-concept studies to in-person meetings with FDA. Dr. Paulin has also provided pathology support for post-market surveillance of medical devices. His experience spans multiple device types including, but not limited to, devices used to treat neurologic and cardiac/cardiovascular conditions. He has also supported research for improvement of biopsy tools, diabetes, and thermal tissue ablation devices. Dr. Paulin enjoys having collaborative interactions with sponsors to help understand and better serve their needs. Dr. Paulin completed his residency and MS degree in comparative medicine and pathology at the University of Minnesota. He is board certified by the American College of Veterinary Pathologists (ACVP), a member of the Society of Toxicologic Pathology (STP) and has co-authored multiple publications involving medical device pathology.
Dr. Rachel Reams joined VPS in 2020 as a Senior Pathologist. She has 17 years of experience in toxicologic pathology including 10 years of experience at a large pharmaceutical company as a member of drug development teams and 7 years of experience with a large contract research organization, and over 30 years of experience in veterinary medicine and pathology. Dr. Reams has a broad range of experience in drug development including early discovery/non-GLP, GLP toxicology, clinical pathology, biomarker development, immunohistochemistry, and pathology peer review.
Kathy Bailey is the Vice President of Corporate Integration for StageBio. Prior to joining StageBio, she served as the General Manager/CEO of Alizée Pathology for five years, guiding the organization through a series of transformations and growth. Having found joy in ‘making order out of chaos’ early in her career, Kathy has spent several decades leading teams in multiple industries through new challenges. In her current role, she is focused on working with company leaders in developing and implementing systems and processes that support a unified company mission, vision, and philosophy.
As StageBio’s Vice President of Corporate Development, Charles Coffman oversees a variety of strategic, operating, and financial initiatives including M&A, commercial, integration, and financial analysis. Prior to StageBio, Mr. Coffman was an investor at Ampersand Capital Partners, a healthcare focused private equity firm, where he was involved in growth equity financings, M&A transactions, and strategy discussions with a variety of healthcare CROs and CDMOs. Mr. Coffman began his career in investment banking at Cowen where he focused on healthcare and technology transactions. He holds a B.A. in Economics-Mathematics with a concentration in financial markets from Colby College.
Carrie joined HSRL, now StageBio, in 2006 and manages all areas of the General Toxicologic Pathology Services division, to include Pathologists, Project Leaders, Quality Assurance, and the pathology support team. She also continues to serve in an essential position for many of StageBio’s client relationships. Carrie plays a key role on StageBio’s executive leadership team, utilizing expertise from her previous roles in pathology support, pathology scheduling, project management, and pricing. Her experience includes responsibility for coordinating all pathology deliverables and deadlines among pathologists, the pathology support team, Quality Assurance and clients. Carrie's comprehensive experience as a project manager, prior to and during her current career, makes her extremely well-suited to manage many of the daily operations at StageBio. Carrie earned her Associate of Arts degree from Frederick Community College and subsequently continued her education at Mount Saint Mary’s University.
Sam has more than 17 years of experience working in biological specimen storage and in the preclinical research industry. In this role at StageBio, he will lead and direct the strategic vision for the company's general paraffin histology facilities as well as short-term and long-term materials archiving services. He was also a founder and owner of HSRL Archives, LLC from 2005-2019. Sam received his BS from James Madison University.
Patty joined StageBio in 2010 as the Controller. Now, as the Vice President of Business Optimization, Patty oversees the IT department, plays a key role in the executive leadership team, and manages company projects related to process improvement and systems development.
Get the latest StageBio news and updates sent straight to your inbox.